Therapeutic effects of HESA-A (a herbal-marine compound) in acute organophosphorus pesticide poisoning

Document Type: Original Research Article

Authors

1 Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Cutaneous Leishmaniasis Research Center, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Forensic Medicine and Toxicology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

4 Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Abstract

Objective: Organophosphorus compounds (OPs) are common causes of poisonings. Atropine and oximes are pharmacological antidotes of OPs. However, because of their adverse effects and insufficient performance, several other compounds have been evaluated as adjuvant therapy. HESA-A is a herbal-marine drug that contains material from Carum carvi (Persian cumin), Penaeus latisculatus (king prawn), and Apium graveolens (celery) with anti-inflammatory and antioxidants properties, which has shown useful effects as adjuvant therapy on some diseases. We have evaluated the effect of HESA-A on 69 moderate to severe acute OPs poisoned patients (44 HESA-A treated and 25 controls) as an adjuvant drug.
Materials and Methods: Two randomized age and sex matched groups of OPs poisoned patients were treated in Medical Toxicology Center of Imam Reza hospital, Mashhad, by conventional therapy with or without HESA-A (50 mg/kg/day orally). The evaluation criteria were total administrated doses of atropine and pralidoxime, intensive care unit (ICU) admission rate, mechanical respiration need, number of hospitalization days and mortality.
Results: There were no significant differences between the morbidity and mortality rate criteria of the two groups; moreover, we did not observe significant adverse effects for HESA-A.
Conclusion: HESA-A did not reduce morbidity and mortality of OPs poisoning and did not induce any major side effect in the patients.

Keywords

Main Subjects


Abbasi MM, Helli S, Monfaredan A, Jahanban-Esfahlan R. 2015a. Hesa-A improves clinical outcome of oral carcinoma by affecting p53 gene expression in vivo. Asian Pac J Cancer Prev, 16: 4169-4172.

Abbasi MM, Mehdipour M, Monfaredan A, Jahanban-Esfahlan R. 2015b. Hesa-A down-regulates erb/b2 oncogene expression and improves outcome of oral carcinoma in a rat model. Asian Pac J Cancer Prev, 16: 6947-6951.

Abdollahi M, Jalali N, Sabzevari O, Hoseini R, Ghanea T. 1997. A retrospective study of poisoning in Tehran. J Toxicol Clin Toxicol, 35: 387-393.

Afshari R, Majdzadeh R, Balali-Mood M. 2004. Pattern of acute poisonings in Mashhad, Iran 1993-2000. J Toxicol Clin Toxicol, 42: 965-975.

Ahmadi A, Mohagheghi M, Karimi M, Seyed Ali G, Naseri M. 2009. Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr Cancer Ther, 8: 71-74.

Ahmadi A, Mohagheghi M, Karimi M, Golestanha SA, Naseri M, Faghihzadeh S, Habibi G. 2010. Therapeutic effects of HESA-A in patients with end-stage metastatic cancers. Integr Cancer Ther, 9: 32-35.

Ahmadi A, Barikbin B, Naseri M, Mohagheghi M. The effect of HESA-A on psoriasis vulgaris. 2008. J Drugs Dermatol, 7: 559-561.

Ahmadi A, Naderi G, Asgary S. 2005a. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res, 31: 1-6.

Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Musavi Jarahi A, Gharipoor M. 2005b. HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit, 11: CR300-303.

Alizadeh AM, Ahmadi A, Paknejad M, Mohammadzadeh M, Mohagheghi M. 2009. The effect of HESA-A, an Herbal-marine compound, on wound healing process: An experimental study. Res J Biol Sc, 4: 298-302.

Amitai G, Adani R, Fishbein E, Meshulam H, Laish I, Dachir S. 2006. Bifunctional compounds eliciting anti-inflammatory and anti-cholinesterase activity as potential treatment of nerve and blister chemical agents poisoning. J Appl Toxicol, 26: 81-87.

Balali-Mood M, Saber H. 2012. Recent advances in the treatment of organophosphorous poisonings. Iran J Med Sci, 37: 74-91.

Balali-Mood M, Ayati MH, Ali-Akbarian H. 2005. Effect of high doses of sodium bicarbonate in acute organophosphorous pesticide poisoning. Clin Toxicol (Phila), 43: 571-574.

Banks CN, Lein PJ. 2012. A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation. Neurotoxicology, 33: 575-584.

Barikbin B, Qeisari M, Saeedi M, Esmailiazad M, Moravvej H, Yousefi M, Ahmadi A. 2010. Efficacy of HESA-A in the treatment of chronic plaque type psoriasis. Iran J Dermatol, 13: 16-19.

Basher A, Rahman SH, Ghose A, Arif SM, Faiz MA, Dawson AH. 2013. Phase II study of magnesium sulfate in acute organophosphate pesticide poisoning. Clin Toxicol (Phila), 51: 35-40.

Bertolote JM, Fleischmann A, Eddleston M, Gunnell D. 2006. Deaths from pesticide poisoning: Are we lacking a global response? Br J Psychiatry, 189: 201-203.

El-Shenawya NS, El-Salmyb F, Al-Eisab RA, El-Ahmaryb B. 2010. Amelioratory effect of vitamin E on organophosphorus insecticide diazinon-induced oxidative stress in mice liver. Pestic Biochem Phys, 96: 101-107.

Etemad L, Moshiri M, Balali-mood M. 2015. Chronic toxicity of OP compounds, in basic and clinical toxicology of organophosphorous compounds. London Springer: p. 79-119.

Fattahi S, Vosough Hosseini S, Aghbali AA, Mehdipour M, Helli S, Damghani H. 2017. Effects of systemic administration of HESA-A on the expression of cyclin D1 and EGFR and E-cadherin in the induced tongue dysplasia in rats. J Dent Res Dent Clin Dent Prospects, 11:201-207.

Mehrbod P, Ideris A, Rahman Omar A, Hair-Bejo M. 2014. Prophylactic effect of herbal-marine compound (HESA-A) on influenza A virus infectivity. BMC Complement Altern Med, 14: 131.

Moallem SA, Ahmadi A, Moshafi M, Taghavi MM. 2010. Teratogenic effects of HESA-A, a natural anticancer product from Iran, in mice. Hum Exp Toxicol, 30: 851-859.

Moallem SA, Ahmadi A, Moshafi M, Taghavi MM. 2011. Teratogenic effects of HESA-A, a natural anticancer product from Iran, in mice. Hum Exp Toxicol, 30:851-859.

Moshiri M, Darchini-Maragheh E, Balali-Mood M. 2012. Advances in toxicology and medical treatment of chemical warfare nerve agents. Daru, 20: 81.

Moshiri M, Alizadeh A, Balali-mood M, 2015. Clinical management of organophosphorus nerve agents’ poisonings, in basic and clinical toxicology of organophosphorous compounds. London Springer; p. 177-213.

Moshiri M, Vahabzadeh M, Etemad L, Hosseinzadeh H. 2013. Failure of intravenous lipid emulsion to reduce diazinon-induced acute toxicity: a pilot study in rats. Iran J Pharm Res, 12: 897-902.

Muhammadnejad S, Zendehdel K, Mazaheri Z, Muhammadnejad A, Haddadi M, Mohagheghi MA, Amanpou S. 2014. Assessment of selective growth inhibitory effects of HESA-A on some human neoplastic cell lines. Basic Clin Cancer Res, 6: 10-15.

Roudkenar MH, Bahmani P, Halabian R, Mohammadi Oushandeh A, Jahanian Najafabadi A, Shokrgozar MA. 2012. HESA-A Exerts its cytoprotective effects through scavenging of free radicals: An in vitro study. Iran J Med Sci, 37: 47-53.

Sadeghi-Aliabadi H, Ahmadi A. 2003. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru, 11: 82-87.

Sadeghi Aliabadi H, Ahmadi A. 2001. Cytotoxicity and antitumor properties of a marine compound on cancer cells (HESA-A). Med J Islamic Acad Sci, 13: 55–61

Schumacher M, Kelkel M, Dicato M, Diederich M. 2011. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2010. Molecules, 16: 5629–5646.

Vahabpour R, Sadat SM, Zabihollahi R, Ahmadi A, Keivani H, Amini S, Siadat SD, Aghasadeghi MR. 2012. In vitro inhibitory effects of the herbal-marine compound HESA-A against replication of human immunodeficiency virus-1. Jundishapur J Microbiol, 5: 315-319.